Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsİbrahim Halil Şahin, Christina Wu|British Journal of Cancer|2019Cited by 409
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Thierry André, Kimmie Ng et al.|The Lancet Oncology|2023Cited by 244